For example in the current Swedish clinical guidelines, combination therapy is recommended for PS0-1 patients with advanced NSCLC without actionable molecular alterations regardless of PD-L1 expression level, while monotherapy remains an alternative in high PD-L1 expression [18]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.